MedPath

Neuromuscular Electrical Stimulation for Intensive Care Unit-acquired Weakness Assessment

Phase 3
Conditions
Polyneuropathy, Critical Illness
Interventions
Device: Neuromuscular electrical stimulation
Device: Sham control
Registration Number
NCT02706587
Lead Sponsor
Institut Mutualiste Montsouris
Brief Summary

The purpose of this study is to determine whether early neuromuscular electrical stimulation is effective in the prevention of neuromuscular weakness in critical ill patients.

Detailed Description

Randomized, controlled study of early electrical neurostimulation (vs sham) in critically ill patients.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
102
Inclusion Criteria
  • All patient
  • Aged of 18 or more
  • With an intended ICU stay of at least 72 hours
  • Mechanically ventilated
Exclusion Criteria
  • Age less than 18 years
  • Pregnant women
  • Preexisting neuromuscular disease
  • Patient bearing a pace maker or an implantable defibrillator.
  • Poly traumatism and/or leg fracture.
  • End stage disease

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Neuromuscular electrical stimulationNeuromuscular electrical stimulationNEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
Sham ControlSham controlNo electrostimulation
Primary Outcome Measures
NameTimeMethod
Medical resuscitation council (MRC) scoreup to 25 months. From date of randomization to the date of ICU discharge
Secondary Outcome Measures
NameTimeMethod
Total duration of mechanical ventilation (days)up to 25 months. From date of randomization to the date of ICU discharge
Length of ICU stay and hospital stay.up to 25 months. From date of randomization to the date of ICU discharge or hospital discharge
Type of hospital dischargeup to 25 months. From date of randomization to the date of hospital discharge

(alive/deceased/rehabilitation/home...)

Trial Locations

Locations (1)

Insitut Mutualiste Montsouris

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath